# Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas

> **NCT05737212** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dawonmedax Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Recurrent High-grade Glioma
- Recurrent Glioblastoma
- Recurrent Anaplastic Astrocytoma
- Recurrent Anaplastic Oligodendroglioma

## Interventions

- **RADIATION:** 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
- **RADIATION:** 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq
- **RADIATION:** 500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq

## Key facts

- **NCT ID:** NCT05737212
- **Lead sponsor:** Dawonmedax Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-05
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial with a revised protocol.
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737212, "Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05737212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*